Analysts await BioAmber Inc. (NASDAQ:BIOA) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.3 EPS, up 60% or $0.18 from last year’s $-0.48 per share.

At the moment 5 analysts are watching BioAmber Inc. (NASDAQ:BIOA), 1 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 2 analysts have a mean sales target of 5.00 million. For the quarter ending Jun-16, 2 analysts have a mean sales target of 10.50 million whilst for the year ending Dec-16, 3 analysts have a mean target of 38.73 million.

In terms of earnings per share, 2 analysts have a -0.21 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.12 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -0.89 EPS.

The biggest institutional shareholders in BioAmber Inc. include Waddell & Reed Investment Management Co which owns 8 million shares in the company valued at $49.84 million. Royce & Associates, LLC is the second biggest holder with 922 K million shares currently valued at 5.70 million whilst Park West Asset Management LLC has 666 K million shares valued at 4.00 million.

Total shares held by institutions as of the most recent company filings are 11,153,856 with a reported 313,550 bought and 123,376 sold. These holdings make up 48.27% of the company’s outstanding shares.

Currently insiders hold 436,102 shares in the business which makes up 1.69% of shares. The biggest holder currently is Mr. Jean-Francois Huc who owns 144,222 shares (0.56% of those outstanding), whilst Michael A. Hartmann holds 123,143 (0.48% of shares outstanding) and Mr. Kurt W. Briner holds 120,630 (0.47% of shares outstanding).

The stock increased 0.76% or $0.03 during the last trading session, hitting $3.99. BioAmber Inc. (NASDAQ:BIOA) has fallen 44.36% over the past 6 months and is downtrending.